How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Executive Summary
Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.
You may also be interested in...
Interview: Celltrion's Journey To The Top
In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.
Interview: Celltrion's Journey To The Top
In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.